Several other research analysts have also weighed in on ICLR. Wells Fargo & Co initiated coverage on Icon in a research report on Tuesday, January 7th. They issued an equal weight rating and a $180.00 price objective for the company. Zacks Investment Research upgraded Icon from a hold rating to a buy rating and set a $191.00 price objective for the company in a research report on Wednesday, December 25th. Citigroup initiated coverage on Icon in a research report on Monday, January 6th. They issued a neutral rating and a $185.00 price objective for the company. Credit Suisse Group reiterated a buy rating and issued a $160.00 price objective on shares of Icon in a research report on Monday, October 28th. Finally, UBS Group set a $160.00 price target on Icon and gave the stock a hold rating in a research report on Friday, October 25th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $169.56.
Shares of Icon stock opened at $168.68 on Friday. The firm has a market capitalization of $9.08 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 2.04 and a beta of 0.70. Icon has a fifty-two week low of $127.58 and a fifty-two week high of $173.00. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.03 and a current ratio of 2.03. The stock has a 50 day moving average of $166.28 and a 200 day moving average of $155.24.
Icon (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $710.40 million during the quarter, compared to analyst estimates of $709.75 million. Icon had a return on equity of 24.86% and a net margin of 13.16%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.54 earnings per share. Analysts forecast that Icon will post 6.89 EPS for the current year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allred Capital Management LLC purchased a new position in shares of Icon during the fourth quarter worth $64,000. Diversified Trust Co boosted its position in shares of Icon by 30.0% during the fourth quarter. Diversified Trust Co now owns 7,753 shares of the medical research company’s stock worth $1,335,000 after buying an additional 1,791 shares during the period. Henry James International Management Inc. boosted its position in shares of Icon by 3.7% during the fourth quarter. Henry James International Management Inc. now owns 30,966 shares of the medical research company’s stock worth $5,333,000 after buying an additional 1,113 shares during the period. Bangor Savings Bank boosted its position in shares of Icon by 2.9% during the fourth quarter. Bangor Savings Bank now owns 8,222 shares of the medical research company’s stock worth $1,416,000 after buying an additional 232 shares during the period. Finally, Lenox Wealth Advisors LLC boosted its position in shares of Icon by 1,700.0% during the fourth quarter. Lenox Wealth Advisors LLC now owns 180 shares of the medical research company’s stock worth $31,000 after buying an additional 170 shares during the period. Institutional investors and hedge funds own 85.82% of the company’s stock.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: Buy Rating
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.